Drugs / Duodopa®
Duodopa®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00335153 | Jan 2008 → Jun 2012 | Parkinson disease | AbbVie | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-01-12 | AbbVie | Regulatory AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease abbvie.com ↗
The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Duodopa | “The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months...” NCT00335153 ↗ |
| Known as | LCIG | “We report the efficacy and adverse effect profile of intraduodenal levodopa-carbidopa intestinal gel (LCIG) infusion from patients treated in a single Australian movement...” PMID 26777085 ↗ Jan 2016 |
| Known as | levodopa-carbidopa intestinal gel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00335153 ↗ |
| Route | Other | “LCIG administration via a permanent PEG-J tube” NCT00335153 ↗ |